Alnylam to Host “RNAi Roundtable” Webcast Series
July 07 2014 - 08:00AM
Business Wire
Alnylam Pharmaceuticals, Inc.
(Nasdaq: ALNY), a leading RNAi therapeutics company, today
announced that it plans to host and webcast a series of online
“RNAi Roundtables” during July and August. Alnylam scientists and
key clinical collaborators will review recent progress from several
of the “Alnylam 5x15” programs and discuss the related disease
areas. Each event will be webcast live on the Investors section of
the company’s website, www.alnylam.com. An audio replay of the
roundtables will be posted on the Alnylam website approximately
three hours after each event.
The RNAi Roundtable topics scheduled to date include:
Patisiran and ALN-TTRsc for the treatment of
Transthyretin-Mediated Amyloidosis (ATTR)
Tuesday, July 15: 12:30 – 2:00 p.m. ET
- Jared Gollob, M.D., Vice President,
Clinical Research
- Moderator: John Maraganore, Ph.D.,
Chief Executive Officer
- Guest Speaker: Philip N. Hawkins, M.B.,
B.S., Ph.D., FRCP, Professor of Medicine, National Amyloidosis
Centre, University College London Medical School
Advances in Delivery of RNAi Therapeutics with Enhanced
Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates
Tuesday, July 22: 11:00 a.m. – 12:00 p.m. ET
- Rachel Meyers, Ph.D., Vice President,
Research and RNAi Lead Development
- Moderator: Laurence Reid, Ph.D., Senior
Vice President and Chief Business Officer
ALN-HBV for the treatment of Hepatitis B Virus (HBV)
Infection
Tuesday, July 29: 9:30 – 10:30 a.m. ET
- Laura Sepp-Lorenzino, Ph.D., Vice
President, Entrepreneur-in-Residence
- Moderator: Laurence Reid, Ph.D., Senior
Vice President and Chief Business Officer
- Guest Speaker: Graham Foster, Ph.D.,
FRCP, Professor of Hepatology at Queen Mary University of
London
ALN-AT3 for the treatment of Hemophilia and Rare Bleeding
Disorders
Thursday, August 7: 9:30 – 10:30 a.m. ET
- Akin Akinc, Ph.D., Director,
Research
- Moderator: John Maraganore, Ph.D.,
Chief Executive Officer
- Guest Speaker: Flora Peyvandi, M.D.,
Ph.D., Head of the Department of Internal Medicine and Angelo
Bianchi Bonomi Hemophilia and Thrombosis Centre, IRCCS Maggiore
Hospital, University of Milan.
ALN-CC5 for the treatment of Complement-Mediated
Diseases
Wednesday, August 13: 9:30 – 10:30 a.m. ET
- Benny Sorensen, M.D., Ph.D., Medical
Director, Clinical Development
- Moderator: Barry Greene, President and
Chief Operating Officer
- Guest Speaker: Anita Hill, MBChB
(Hons), MRCP, FRCPath, Ph.D., Consultant Haematologist for Leeds
Teaching Hospitals NHS Trust, UK, and Honorary Senior Lecturer at
the University of Leeds
Alnylam plans to schedule additional RNAi Roundtables covering
other pipeline programs to take place in the coming weeks,
including ALN-AS1 for the treatment of hepatic porphyrias;
ALN-PCSsc for the treatment of hypercholesterolemia; and ALN-AAT
for the treatment of AAT deficiency-associated liver disease. The
topics, dates, and times of these events will be posted on the
Capella section of the company’s website,
www.alnylam.com/capella.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi. The company is
leading the translation of RNAi as a new class of innovative
medicines with a core focus on RNAi therapeutics as genetic
medicines, including programs as part of the company’s “Alnylam
5x15TM” product strategy. Alnylam’s genetic medicine programs are
RNAi therapeutics directed toward genetically defined targets for
the treatment of serious, life-threatening diseases with limited
treatment options for patients and their caregivers. These include:
patisiran (ALN-TTR02), an intravenously delivered RNAi therapeutic
targeting transthyretin (TTR) for the treatment of TTR-mediated
amyloidosis (ATTR) in patients with familial amyloidotic
polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi
therapeutic targeting TTR for the treatment of ATTR in patients
with TTR cardiac amyloidosis, including familial amyloidotic
cardiomyopathy (FAC) and senile systemic amyloidosis (SSA);
ALN-AT3, an RNAi therapeutic targeting antithrombin (AT) for the
treatment of hemophilia and rare bleeding disorders (RBD); ALN-CC5,
an RNAi therapeutic targeting complement component C5 for the
treatment of complement-mediated diseases; ALN-AS1, an RNAi
therapeutic targeting aminolevulinic acid synthase-1 (ALAS-1) for
the treatment of hepatic porphyrias including acute intermittent
porphyria (AIP); ALN-PCS, an RNAi therapeutic targeting PCSK9 for
the treatment of hypercholesterolemia; ALN-AAT, an RNAi therapeutic
targeting alpha-1 antitrypsin (AAT) for the treatment of AAT
deficiency-associated liver disease; ALN-TMP, an RNAi therapeutic
targeting TMPRSS6 for the treatment of beta-thalassemia and
iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting
angiopoietin-like 3 (ANGPTL3) for the treatment of genetic forms of
mixed hyperlipidemia and severe hypertriglyceridemia; ALN-AC3, an
RNAi therapeutic targeting apolipoprotein C-III (apoCIII) for the
treatment of hypertriglyceridemia; and other programs yet to be
disclosed. As part of its “Alnylam 5x15” strategy, as updated in
early 2014, the company expects to have six to seven genetic
medicine product candidates in clinical development - including at
least two programs in Phase 3 and five to six programs with human
proof of concept - by the end of 2015. Alnylam is also developing
ALN-HBV, an RNAi therapeutic targeting the hepatitis B virus (HBV)
genome for the treatment of HBV infection. The company’s
demonstrated commitment to RNAi therapeutics has enabled it to form
major alliances with leading companies including Merck, Medtronic,
Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist,
GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and
Genzyme, a Sanofi company. In March 2014, Alnylam acquired Sirna
Therapeutics, a wholly owned subsidiary of Merck. In addition,
Alnylam holds an equity position in Regulus Therapeutics Inc., a
company focused on discovery, development, and commercialization of
microRNA therapeutics. Alnylam scientists and collaborators have
published their research on RNAi therapeutics in over 200
peer-reviewed papers, including many in the world’s top scientific
journals such as Nature, Nature Medicine, Nature Biotechnology,
Cell, the New England Journal of Medicine, and The Lancet. Founded
in 2002, Alnylam maintains headquarters in Cambridge,
Massachusetts. For more information, please visit
www.alnylam.com.
Alnylam Pharmaceuticals, Inc.Cynthia Clayton,
617-551-8207Vice President, Investor Relations andCorporate
CommunicationsorSpectrumLiz Bryan (Media), 202-955-6222
x2526
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2023 to Mar 2024